// App-Quantinova.ai

2458 : Targeting checkpoint kinase 1 (CHK1) with the small molecule inhibitor LY2606368 mesylate monohydrate in models of high-risk pediatric cancer yields significant antitumor effects

Researchers

Presenter

  • Caitlin D. May

Principal Investigators

  • Richard Beckmann

  • Wayne Blosser

  • Michele Dowless

  • Alle Van Wye

  • Teresa Burke

  • Gerard Oakley

  • Jennifer Stephens

  • Julie Stewart

  • Beverly Falcon

  • Louis Stancato

Medical Centers

  • Eli Lilly and Company, Indianapolis, IN

  • Advanced Testing Laboratory, Indianapolis, IN.

Locations

  • United States

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Rhabdomyosarcoma

  • Hepatoblastoma

  • Retinoblastoma

  • Neuroblastoma

  • Sarcoma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Checkpoint kinase 1

  • checkpoint kinase 2

  • Cluster of Differentiation 31

  • Proliferation marker protein Ki-67

Drug/Treatment

  • LY2606368

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved